What the 10-year evidence actually shows

Survival figures from a decade of follow-up place OATS's overall clinical success between approximately 72% and 86%, with Lysholm and IKDC scores remaining significantly above pre-operative baseline at ten years — though a modest attenuation occurs after year five.

The strongest direct evidence comes from the Gudas prospective randomised trial, the only RCT in young athletes to reach a genuine 10-year endpoint. Treatment failure occurred in 14% of OATS patients compared with 38% in the microfracture group — a divergence that opens decisively between years five and ten, meaning shorter follow-up studies consistently understate the performance gap between the two techniques.

A 2024 cohort combining OATS with medial open-wedge high tibial osteotomy in 66 knees adds structural depth to those figures. At a mean follow-up of 9.49 years, Kaplan-Meier survivorship reached 96.7%, with only two patients requiring conversion to total knee replacement. Second-look arthroscopy confirmed 100% cartilage regeneration, with true hyaline cartilage identified in 49 of the 57 knees assessed — and Knee Society Scores rising from 48.3 to 90.4.

The counter-figure deserves equal prominence: up to 28–33% of OATS cases reach surgical failure or require revision within a decade.

At the furthest data point currently in the literature, a 2025 JOCR case report documented structurally intact OAT plugs at 18-year re-arthroscopy — a single case, but one without parallel in published evidence. For context, a 2026 ACI RCT follow-up found 71% survivorship at ten years, positioning OATS as competitive for the focal defect sizes it is designed to address.

How OATS and microfracture outcomes diverge over time

The divergence between OATS and microfracture is not visible early. At two to three years post-operatively, both procedures can appear broadly comparable — functional scores improve, patients resume activity, and short-term series show reasonable satisfaction in both groups. This is precisely why early follow-up data underestimate the real-world difference between the two techniques over a sporting career.

What changes is the underlying tissue. Microfracture recruits marrow-derived cells that form fibrocartilage — a mechanically inferior substitute that progressively breaks down under load. Over time, this deterioration can damage the subchondral bone plate, narrowing the options available if a revision procedure becomes necessary. OATS, by contrast, transfers structurally intact hyaline osteochondral plugs that integrate with the surrounding tissue and remain durable — as the long-term arthroscopic evidence described in the previous section confirms.

The cumulative effect of this structural difference is captured in the Gudas cohort noted above: the gap between 14% and 38% failure does not materialise at five years; it accumulates through the second half of a decade. Return-to-sport rates follow the same pattern — 84–100% for OATS versus 44–83% for microfracture — and athletes returning after microfracture more frequently compete at a reduced level rather than their pre-injury tier.

A 2026 systematic review of 19 studies and 736 patients adds further breadth: OATS produced IKDC score improvements of 40.49 points compared with 30.9 for minced cartilage repair, with greater VAS pain reduction (-4.27 versus -3.7). Microfracture's historical role as a first-line procedure is giving way to this accumulating evidence; it is not a modern first-line choice for patients expecting sustained return to sport.

Which patients are best suited to OATS

Lesion size is the primary gating criterion. OATS works best for focal full-thickness defects under 2–2.5 cm²; mosaic configurations — multiple plugs tiled across a single site — can extend coverage to approximately 4 cm², though donor-site demands increase with every additional plug harvested.

Age shapes candidacy as much as defect dimensions. The conventional upper threshold sits at around 45–50 years, but within that range, patients under 25 with lesions smaller than 2 cm² carry the strongest predictor profile for returning to the same competitive level of sport. Both factors appear to operate independently, meaning a younger patient with a larger lesion, or an older patient with a small one, sits in a more uncertain position.

Prior microfracture is a meaningful red flag. When marrow-stimulation has previously disrupted the subchondral bone plate, the structural foundation an osteochondral plug needs in order to integrate is compromised — and published ten-year outcomes are correspondingly worse. Patients who have already had microfracture should raise this specifically during consultation rather than assuming it does not affect their options.

Alignment is equally non-negotiable. Varus or valgus malalignment concentrates load on the repair site and accelerates failure; the 96.7% survivorship reported in the Han 2024 cohort was achieved in patients whose alignment had already been corrected, most commonly with concurrent medial open-wedge high tibial osteotomy. If malalignment is present, correcting the mechanical axis is part of the procedure, not an optional addition.

The medial femoral condyle is the most common and best-studied treatment site, accounting for the majority of cases in systematic review data.

OATS addresses focal, contained defects. Patients with diffuse cartilage loss across an entire compartment are outside its appropriate remit — a distinction that a consultant assessment, including cartilage-sensitive MRI (onMRI™ cartilage mapping can define lesion borders and subchondral status before the decision is made), will establish clearly.

Donor site morbidity: what it means and how common it is

Every osteochondral plug transferred to the defect site must first be harvested from elsewhere in the patient's own knee — typically the peripheral trochlea or the intercondylar notch, areas that bear relatively little load during normal walking and sport. Creating a secondary wound within the same joint carries its own risk profile, and patients deserve a clear account of it rather than fine-print reassurance.

Adult cohort data place donor site morbidity at approximately 7.8% — not trivial, but manageable in most cases. Reported problems include persistent pain around the harvest site, fibrocartilage fill rather than true hyaline regeneration in the donor cavity, and, in a minority of cases, localised chondral damage at graft tunnel margins. In paediatric cohorts the rate of subsequent donor-site surgery rises to around 13.5%, driven primarily by chondroplasty for fibrocartilage overgrowth at the harvest site — a finding that reinforces the importance of careful patient selection.

The number and diameter of plugs taken directly affects this burden. A single plug for a contained defect under 1 cm² creates a modest harvest wound; a mosaic configuration covering 3–4 cm² requires multiple cores and a correspondingly larger footprint. This relationship is one of the core reasons OATS candidacy is limited to roughly 2–2.5 cm² for single-plug transfer. Where defects exceed that threshold and autograft is simply insufficient, fresh osteochondral allograft (OCA) sidesteps the donor-site problem by using cadaveric tissue — a separate pathway not covered in detail here.

Being single-stage — performed arthroscopically or via a small mini-arthrotomy — OATS is operationally simpler than two-stage cell-culture pathways such as MACI or ACI, and avoids allograft regulatory considerations. For lesions that fall within the appropriate size range, that procedural straightforwardness is a genuine practical advantage.

How rehabilitation and augmentation affect long-term repair

Structural repair quality after OATS is not fixed at the moment the plugs are pressed into position. Two sets of factors shape graft integration over the months and years that follow — those within the surgeon's control at the time of surgery, and those within the patient's control during rehabilitation.

What the surgical team can optimise

Biological augmentation at the time of plug transfer is a documented outcome modifier. Adding bone marrow aspirate concentrate (BMAC) to the graft site materially improves structural repair quality. A comparative study found MOCART 2.0 cartilage-repair scores of 96.1 with OATS plus BMAC and a structured 12-week rehabilitation programme, against 80.2 for OATS alone on the same programme and 71.7 when an abbreviated six-week protocol was used. BMAC here functions as a surgical adjunct at the point of graft implantation — distinct from standalone biologic injection treatments. Second-look arthroscopy data from well-designed cohorts confirm that OATS can produce true hyaline cartilage rather than fibrocartilage fill at the repair site, a quality distinction with direct implications for long-term durability.

What the patient controls

Evidence-based OATS-specific rehabilitation pathways recommend partial weight-bearing for approximately four to six weeks, progressive loading to twelve weeks, sport-specific conditioning from around four to six months, and return to competitive sport at nine to twelve months. These timelines reflect the biology of osseointegration, not institutional conservatism. Loading the graft site before that integration is secure risks mechanical failure of a repair that required a single surgical opportunity to create — a consideration worth understanding clearly before committing to the procedure.

Return to sport and what active patients can realistically expect

Published series consistently place return-to-sport rates for OATS between 84% and 100% in active cohorts — a figure that carries weight precisely because the only randomised trial with a genuine ten-year endpoint provides its floor, not just its ceiling. The Gudas prospective RCT found that 84% of athletes who underwent OATS returned to their pre-injury competitive level at ten years, against 44–83% for those who had microfracture, with many in the latter group competing at a reduced tier or leaving their sport entirely.

The patient characteristics most strongly associated with reaching that same competitive level — principally lesion size and age, discussed in the selection section above — also shape the shape of recovery over time. Functional scores rise steeply in the first two to three years, remain significantly elevated through year ten, but show modest attenuation from around year five onwards. Planning for sustained improvement, rather than indefinite gains, is the realistic frame.

Beyond ten years, the evidence base thins. Prospective controlled data on isolated OATS survivorship and return-to-sport rates specifically in high-demand athletes remain limited; most long-duration evidence derives from combined-procedure or observational cohorts. That is clinically honest rather than alarming — the ten-year data are robust — but it is information an active patient deserves before committing.

Access adds a further practical layer. A 2025 UK nationwide survey across 19 centres found OATS performed at fewer than half of them, accounting for just 29 procedures over five years against 1,579 microfractures. Where a patient's lesion profile and activity level make OATS the more appropriate choice, this practice-evidence gap underlines the value of specialist cartilage assessment rather than accepting the most readily available option.

1. [1] Cartilage regeneration and long term survival in medial OA knee patients treated with HTO and OATS. (2024). https://doi.org/10.1016/j.jor.2024.06.024 https://doi.org/10.1016/j.jor.2024.06.024
2. [2] Evaluating single-stage cartilage treatments in the knee: A systematic review and meta-analysis of OATS and MCR techniques. (2026). https://doi.org/10.1016/j.jor.2025.12.052 https://doi.org/10.1016/j.jor.2025.12.052
3. [3] The management of cartilage defects of the knee and injection therapy – a collaborative and retrospective study. (2025). https://doi.org/10.1016/j.knee.2025.11.013 https://doi.org/10.1016/j.knee.2025.11.013